Author: Elliott Renft

Evonik Interview: How Recombinant Albumin De-Risks Cell Therapy Manufacturing

By

Introduction Our partner Evonik has published a detailed interview featuring InVitria’s Director of Business Development, Jake Hanks. The discussion focuses on how recombinant human serum albumin helps biopharma manufacturers reduce risks in cell therapy production through greater consistency, purity, and supply security. Full Interview Link Read the complete Evonik interview Partnership Overview Evonik distributes InVitria’s …

InVitria Joins NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT)

By

InVitria has joined the NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT) as an industry member. The partnership brings together CMaT’s leadership in cell manufacturing research with InVitria’s expertise in animal-origin-free recombinant proteins to support consistent, scalable cell therapy manufacturing. CMaT works to transform the manufacture of cell-based therapeutics into large-scale, reproducible, and high-quality …